ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Chitosan gold nanogel containing Rova-Typhoid immunotoxins against the DLL3 receptor has a promising effect on small-cell lung cancer.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploiting the Notch pathway in HTLV-1-driven adult T-cell leukemia/lymphoma: a mini-review.Annals of hematology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SCLC (small-cell lung cancer) is hardly treated with chemotherapy alone, even though it was initially sensitive to the drug. A novel therapeutic combination for treating diseases that have resisted typical first-line treatments is available with immunotoxin-based anticancer medicines. The use of delta-like ligand 3 (DLL3) in target treatment has potential because of the high expression of DLL3 in patients with SCLC. Nanoparticles are gaining popularity in developing new therapeutics, with gold nanoparticles (AuNPs) being investigated as potential cancer treatments. Emerging evidence indicates that AuNPs stabilized with chitosan (CS) have interesting biological functions. Therefore, in this study, we aimed to synthesize chitosan nanogel to deliver Rova-Typhoid immunotoxins to target cancer cells. In this research, we synthesized CS-AuNPs and CS-Rova-Typh-AuNPs and analyzed their cytotoxicity in small-cell lung (A549) cancer cells and HUVEC cell lines. Then, we evaluated the inhibitory concentration (IC50), cell cycle, and mRNA expression. Free AuNPs did not show cytotoxic effects on our cell lines; however, the inhibitory concentration of Rova-Typh immunotoxin is reduced when loaded into CS-AuNPs. Besides, immunotoxin-loaded nanogel induces late apoptosis in A549 cells and effectively induces sub-G1 cell arrest. Moreover, immunotoxin-loaded nanogel causes downregulation in DLL3, HES1, and NOTCH1 genes, which are involved in the Notch signaling pathway. Our results indicate that CS-AuNPs were an effective Rova-Typh delivery means, and Rova-Typhoid immunotoxin induces apoptosis in cancer cells through inhibiting DLL3, which is a Notch signaling ligand.
Indexed as
Identifiers
40455231What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.